NCT02578069已完成不适用
A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the NOVA Sirolimus Eluting Stent Versus the Apollo Stent
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 272
- 试验地点
- 2
- 主要终点
- In stent restenosis rate (> 50% restenosis)
研究概览
简要总结
Prospective, multi-center, randomized 1:1 single blind trial using NOVA sirolimus eluting stent versus Apollo bare metal stent conducted in approximately 15 interventional neurology centers in China. The study was sponsored by Sino Medical Sciences Technology Inc.
详细描述
The study will enroll 264 subjects overall in two groups (randomized 1:1). The study follow-up will occur at 1, 6 and 12 months post-stent implantation. All patients will undergo angiography assessment (DSA/CTA) at 12 months follow-up. Angiography assessment will be performed at baseline (pre- and post-procedure) and 12 months follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 to 75 years of age;
- •Primary or recurrent symptomatic intracranial arteriostenosis through the internal medicine treatment (i.e. stroke or transient ischemic attack within 90 days during the treatment with at least one anti-thrombotic drugs and vascular risk factor intervention e.g. hypertensors for hypertension and hypolipidemics for hyperlipidemia);
- •No transient ischemic attack (TIA) or ischemic stroke occurred within 2 weeks prior to stenting procedure;
- •≥70% stenosis of intracranial responsible vessel under the DSA angiography (as judged through the WASID method);
- •Poor blood circulation in the side branch of responsible vessel area under the angiography within one week prior to stenting procedure:
- •Score of blood circulation in the side branch under the DSA <3 or blood flow rate peak ≥200cm/s at the systolic phase under the transcranial doppler ultrasonic examination (TCD); or no apparent side branch compensation in the responsible vessel area under CTA or score of blood circulation in the side branch under the CTA <2;
- •The target lesion reference diameter must be visually estimated to be ≥2.0 mm in diameter, and lesion length must be <15 mm; no lesion observed in the distal vessel;
- •Atherosclerosis lesions;
- •Written informed consent.
排除标准
- •>70% intracranial large-vessel stenosis beyond the responsible vessel;
- •>70% stenosis observed at the intracranial large-vessel distal to the responsible vessel or >70% stenosis observed at the intracranial/extracranial large-vessel proximal to the responsible vessel;
- •Acute ischemic stroke within 3 weeks;
- •Obstruction of perforating branch artery under the skull MRI;
- •Intracranial hemorrhage in the angiopathic area within 6 weeks;
- •Patient was treated by thrombolytic therapy within 24 hours;
- •Patients underwent surgery within 30 days or plan for surgery within 3 months post-stenting procedure;
- •Severe calcified lesions;
- •Patients have been treated by intracranial/extracranial stenting procedures prior to this study;
- •Nonatherosclerosis lesions;
- •Patients with potential sources for cardiac embolism;
- •Concomitant intracranial tumor, aneurysm or intracranial arteriovenous malformation;
- •Known hypersensitivity or contraindication to aspirin, heparin, antiplatelet medication specified for use in the study, sirolimus, poly(lactic-co-glycolic acid) polymers, or poly(n-butyl methacrylate);
- •Hemoglobin <100g/L, platelet count <100,000 cells/mm3, International normalized ratio (INR) >1.5 (irreversible) or uncorrectable hemorrhagic factors;
- •Serious neural dysfunction due to the responsible angiopathy as the sequel of cerebral infarction (mRS≥3);
- •Known liver or renal insufficiency (ALT> 3x upper limit or AST > 3x upper limit, creatinine > 1.5x upper limit);
- •Life expectancy < 2 years;
- •Pregnant/lactating female patients;
- •Patients with cognitive impairment or mental diseases;
- •The patient participated in another investigational device or drug study within 3 months;
- •Inapplicable for intravascular stenting treatment as per investigators judgment.
结局指标
主要结局
In stent restenosis rate (> 50% restenosis)
时间窗: 12 months post-procedure
Angiography assessment at 12 months post-procedure
次要结局
- Non-target vessels ischemic stroke event(between 30 days and 1 year post-procedure)
- Target vessel ischemic stroke event(between 30 days and 1 year post-procedure)
- Cerebral parenchyma hemorrhage, subarachnoid hemorrhage and intraventricular bleeding events(between 30 days and 1 year post-procedure)
- Death event(between 30 days and 1 year post-procedure)
- National Institutes of Health Stroke Scale (NIHSS) evaluation(at 1 and 12 months)
- Stroke and death events(within 30 days after stenting)
- Acute procedural success rate (stenosis < 30%)(1 year)
- modulate RANK score （mRS）evaluation(at 1 and 12 months)
- Montreal Cognitive Assessment (MoCA) evaluation(at 1 and 12 months)
- Recurrent ischemic stroke in the involved vascular area(between 30 days and 1 year post-procedure)
- Target vessel stroke or death events(within 30 days after stenting)
- Transient ischemic attack event(within 1 year post-procedure)
- EQ-5D score evaluation(at 12 months)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
3 期
Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)Coronary Heart DiseaseNCT02448524Micell Technologies428
已完成
不适用
Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCEIschemic Heart DiseaseCoronary AtherosclerosisCoronary Artery StenosisCoronary Artery DiseaseNCT02681016Meshalkin Research Institute of Pathology of Circulation610
进行中（未招募）
不适用
Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels - TRANSFORM IICoronary Artery StenosisCoronary Artery DiseaseNCT04893291Fondazione Ricerca e Innovazione Cardiovascolare ETS1,820
已完成
4 期
Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)Coronary DiseaseNCT00133237Deutsches Herzzentrum Muenchen607
已完成
不适用
The Direct III Post Market StudyCoronary Artery DiseaseNCT02693158Svelte Medical Systems, Inc.440